Valuation: Zai Lab Limited

Market Cap 2.3B 40.28B 2.02B 1.87B 1.72B 3.25B 220B 3.32B 22.29B 8.74B 108B 8.64B 8.46B 374B P/E 2026 *
-9.25x
P/E 2027 * -11x
Enterprise Value 1.86B 32.53B 1.63B 1.51B 1.39B 2.63B 178B 2.68B 18B 7.06B 87.38B 6.98B 6.83B 302B EV / Sales 2026 *
4.14x
EV / Sales 2027 * 3.22x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
3 years 270.64
Extreme 270.64
810
5 years 270.64
Extreme 270.64
2,446.85
10 years 270.64
Extreme 270.64
3,693.35
Manager TitleAgeSince
Chief Executive Officer 61 2014-03-31
Director of Finance/CFO 58 2023-07-06
President 62 2022-11-30
Director TitleAgeSince
Chairman 61 2014-03-31
Director/Board Member 83 2016-12-31
Director/Board Member 75 2016-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+43.36%-.--% - - 2.3B
-0.22%+2.04%+16.21%-8.03% 67.61B
-0.63%-7.39%+36.54%+199.82% 51.6B
+0.36%+40.00%+40.00%+40.00% 43B
-1.26%-0.39%-49.63%-53.84% 40.94B
+4.96%+0.27%+57.04%-24.80% 29.4B
-1.85%-18.08%+103.86%-47.07% 27.09B
-2.12%-1.20%+63.23%+84.42% 23.32B
-0.67%+1.48%+10.61%+188.35% 19.92B
-2.12%-3.92%+56.13%+130.60% 16.91B
Average +3.95%-3.29%+37.11%+56.61% 35.53B
Weighted average by Cap. +0.02%-3.06%+30.63%+47.56%

Financials

2026 *2027 *
Net sales 449M 7.85B 394M 365M 335M 634M 42.95B 647M 4.34B 1.7B 21.09B 1.68B 1.65B 72.83B 596M 10.42B 522M 484M 445M 842M 57B 858M 5.77B 2.26B 27.99B 2.24B 2.19B 96.67B
Net income -241M -4.22B -211M -196M -180M -341M -23.06B -347M -2.33B -915M -11.32B -905M -885M -39.1B -156M -2.74B -137M -127M -117M -221M -14.98B -226M -1.51B -594M -7.35B -588M -575M -25.4B
Net Debt -443M -7.75B -389M -360M -331M -626M -42.41B -639M -4.29B -1.68B -20.83B -1.66B -1.63B -71.93B -387M -6.78B -340M -315M -289M -547M -37.06B -558M -3.75B -1.47B -18.2B -1.45B -1.42B -62.85B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
20.49USD
Average target price
33.30USD
Spread / Average Target
+62.53%

Quarterly revenue - Rate of surprise